Zynex develops, manufactures, markets and sells medical devices used for nerve stimulation, pain management, and rehabilitation, as well as non-invasive fluid, sepsis, and laser-based pulse oximetry ...

Zynex, Inc. ( NASDAQ:ZYXI ) just released its latest full-year report and things are not looking great. It wasn't ...

Zynex (NASDAQ:ZYXI – Get Free Report) had its price objective lowered by equities researchers at HC Wainwright from $17.00 to $15.00 in a research note issued on Wednesday,Benzinga reports. The ...

Law Offices of Howard G. Smith announces an investigation on behalf of Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI) investors concerning the Company's possible violations of federal ...

Fintel reports that on March 12, 2025, Ladenburg Thalmann downgraded their outlook for Zynex (NasdaqGS:ZYXI) from Buy to ...

Fintel reports that on March 12, 2025, RBC Capital downgraded their outlook for Zynex (NasdaqGS:ZYXI) from Outperform to ...

The Law Offices of Frank R. Cruz announces an investigation of Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI) on behalf of investors concerning the Company's possible violations of federal ...

Zynex specializes in non-invasive pain management and patient monitoring, with promising advancements. Read why I think ZYXI ...

Zynex (ZYXI) stock drops as RBC Capital Market downgrades following the company's Q4 2024 earnings report. Read more here.

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of ...

RBC Capital downgraded Zynex (ZYXI) to Sector Perform from Outperform with a price target of $5.50, down from $11. The firm says the company’s ...

Despite a net loss and TRICARE payment suspension, Zynex Inc (ZYXI) shows resilience with revenue growth and strategic ...